



0590

#5 2100

PATENT
Docket No. GZ 2104.00

RECEIVED
JAN 18 2001
TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231 on October 31, 2001.

Peggy Nichols
Name of Person signing: Peggy Nichols

In re Application for:

Charles A. NICOLETTE

Serial No.: 09/931,969

Filing Date: August 17, 2001

For: THERAPEUTIC COMPOUNDS FOR
OVARIAN CANCER

Group Art Unit: 1614

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☒ Within three months of the application filing date or before receipt of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of \$* is enclosed.

01/16/2002 HGBREH1 00000165 501189 09931969

01 FC:125 180.00 CH

- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; according, no fee is believed to be due.
- ☐ After receipt of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

This Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the U.S. Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-1189** referencing 19442-7235, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: Oct. 31, 2001

By: Antoinette F. Konski
Antoinette F. Konski
Registration No. 34,202

McCutchen Doyle Brown & Enersen LLP
Three Embarcadero, Suite 1800
San Francisco, California 94111-4067
Telephone: (650) 849-4400
Facsimile: (650) 849-4800

Form PTO-1449	Docket No. GZ 2104.00	Appl. No. 09/931,969
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	
(use several sheets if necessary)	Filing Date: 08/17/2001	Group Art Unit: 1614

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	07/28/87	4,683,195	Mullis et al.			
	2.	07/28/87	4,683,202	Mullis			
	3.	06/28/88	4,754,065	Levenson et al.			
	4.	01/24/89	4,800,159	Mullis et al.			
	5.	08/08/95	5,440,013	Kahn			
	6.	11/17/98	5,837,249	Heber-Katz et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
	7.	08/01/96	WO 96/23060	The Government of the United States of America			

OTHER DOCUMENTS -



(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	8. <input checked="" type="checkbox"/>	Altman, J.D. et al., "Phenotypic analysis of antigen-specific T lymphocytes" (1996) <i>Science</i> 274 (5284):94-96
	9. <input checked="" type="checkbox"/>	Bertoni, R. et al., "Human class I supertypes and CTL repertoires extend to chimpanzees" (1998) <i>J. Immunol.</i> 161 :4447-4455
	10. <input checked="" type="checkbox"/>	Boczkowski, D. et al., "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo" (1996) <i>J. Exp. Med.</i> 184 :465-472
	11. <input checked="" type="checkbox"/>	Bordignon, C. et al., "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" (1989) <i>PNAS USA</i> 86 :6748-6752
	12. <input checked="" type="checkbox"/>	Carter, B.J., "Adeno-associated virus vectors" (1992) <i>Curr. Op. Biotechnol.</i> 3 :533-539
	13. <input checked="" type="checkbox"/>	Caruso, A. et al., "Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation" (1997) <i>Cytometry</i> 27 :71-76
	14. <input checked="" type="checkbox"/>	Correll, P.H. et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells" (1989) <i>PNAS USA</i> 86 :8912-8916
	15. <input checked="" type="checkbox"/>	Coulie, P.G., "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?" (1997) <i>Molec. Med. Today</i> 3 :261-268
	16. <input checked="" type="checkbox"/>	Culver, K. et al., "Lymphocytes as cellular vehicles for gene therapy in mouse and man" (1991) <i>PNAS USA</i> 88 :3155-3159
	17. <input checked="" type="checkbox"/>	Dharanipragada, R. et al., "The absolute configuration of an intermediate in the asymmetric synthesis of unusual amino acids" (1992) <i>Acta. Cryst.</i> C48 :1239-1241

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket No. GZ 2104.00		APPL. NO. 09/931,969	
<div style="text-align: center;">  </div>		<div style="text-align: center;">  </div>			
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Charles A. NICOLETTE			
(use several sheets if necessary)		Filing Date: 08/17/2001		Group Art Unit: 1614	
18.	X Dharanipragada, R. et al., "Synthetic linear and cyclic glucagon antagonists" (1993) <i>Int. J. Peptide Protein Res.</i> 42(1) :68-77				
19.	X DiMaio, J. et al., "Synthesis of chiral piperazin-2-ones as model peptidomimetics" (1989) <i>J. Chem. Soc. Perkin Trans.</i> 1(9) :1687-1689				
20.	X Feltkamp, M.C.W. et al., "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" (1995) <i>Immunol. Lett.</i> 47 :1-8				
21.	X Ferguson, et al. "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" (1988) <i>Ann. Rev. Biochem.</i> 57 :285-320				
22.	X Fujihashi, K. et al., "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" (1993) <i>J. Immunol. Meth.</i> 160 :181-189				
23.	X Garvey D.S. et al., "3,4-disubstituted γ -lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" (1990) <i>J. Org. Chem.</i> 55(3) :936-940				
24.	X Hruby, V.J., "Conformational restrictions of biologically active peptides via amino acid side chain groups" (1982) <i>Life Sciences</i> 31 :189-199				
25.	X Hruby, V.J. et al. "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" (1990) <i>Biochem J.</i> 268 :249-262				
26.	X Isakov, N. et al., "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" (1995) <i>J. Exp. Med.</i> 181 :375-380				
27.	X Jones, R.C.F. and G.J. Ward, "Amide bond isosteres: imidazolines in pseudopeptide chemistry" (1988) <i>Tetrahedron Lett.</i> 29(31) :3853-3856				
28.	X Kahn, M. and S. Bertenshaw, "The incorporation of β -turn prosthetic units into merrifield solid phase peptide synthesis" (1989) <i>Tetrahedron Lett.</i> 30(18) :2317-2320				
29.	X Karlsson, S. et al., "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" (1986) <i>The EMBO J.</i> 5(9) :2377-2385				
30.	X Kawakami, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" (1994) <i>PNAS USA</i> 91(9) :3515-3519				
31.	X Kazmierski, W. M. and V.J. Hruby, "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of α,β -dimethyl-phenylalanine and α,β -dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" (1991) <i>Tetrahedron Lett.</i> 32(41) :5769-5772				
32.	X Kazmierski, W.M. et al., "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" (1991) <i>J. Am. Chem. Soc.</i> 113 :2275-2283				
33.	X Kemp, D.S. and P.E. McNamara, "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent β -turn-inducing dipeptide analogue" (1985) <i>J. Org. Chem.</i> 50 :5834-5838				
34.	X Kemp, D.S. and B.R. Bowen, "Conformational analysis of peptide-functionalized diacylaminoepindolidiones ^1H NMR evidence for β -sheet formation" (1988) <i>Tetrahedron Lett.</i> 29(40) :5081-5082				
35.	X Kemp, D.S. and W.E. Stites, "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diaza-cyclodeca-2, 7-dione The dilactam of L- α , γ -diaminobutyric acid and D-glutamic acid: A β -turn template" (1988) <i>Tetrahedron Lett.</i> 29(40) :5057-5060				
EXAMINER:		DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					

RECEIVED

FEB 08 2002

TECH CENTER 1600/2900

DO/SR/08 (2/92)
Sheet 3 of 3

RECEIVED

Form PTO-1449		Docket No. GZ 2104.00	App. No. 09/931,969
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		Applicant(s) Charles A. NICOLETTE	
		Filing Date: 08/17/2001	Group Art Unit: 1614
36.	Kemp, D.S. and T.P. Curran, "(2, 5S, 8S, 11S)-1-acetyl-1, 4-diaza-3-keto-5-carboxy-10-thia-tricyclo-[2.8.0 ^{4,8}]-ridecane, 1 the preferred conformation of 1 (1= α temp-OH) and its peptide conjugates α temp-L-(Ala) _n -OR (n=1 to 4) and α -temp -L-Ala-L-Phe-Lys(ϵ Boc)-L-Lys(ϵ -Boc)-NHMe studies of templates for α -helix formation" (1988) <i>Tetrahedron Lett.</i> 29(39) :4935-4938		
37.	Kemp, D.S. and J.S. Carter, "Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives) as γ -turn templates" (1989) <i>J. Org. Chem.</i> 54 :109-115		
38.	McGrory, W.J. et al., "Short communications: A simple technique for the rescue of early region I mutation into infectious human adenovirus type 5" (1988) <i>Virology</i> 163 :614-617		
39.	Merrifield, R.B., "New approaches to the chemical synthesis of peptides" (1967) <i>Recent Progress in Hormone Res.</i> 23 :451-482		
40.	Miyake, A. et al., "Synthesis and angiotensin converting enzyme inhibitory activity of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives" (1984) <i>J. Takeda Res. Labs.</i> 43(3/4) :53-76		
41.	Mosier, D.E. et al., "Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160" (1993) <i>PNAS. USA</i> 90 :2443-2447		
42.	Muzyczka, "Use of adeno-associated virus as a general transduction vector for mammalian cells" (1992) <i>Curr. Top. Microbiol. Immunol.</i> 158 :97-129		
43.	Nagai, U. and K. Sato, "Synthesis of a bicyclic dipeptide with the shape of β -turn central part" (1985) <i>Tetrahedron Lett.</i> 26(5) :647-650		
44.	Nair, S. et al., "Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro" (1992) <i>J. Exp. Med.</i> 175 :609-612		
45.	Olson, G.L. et al., "Design and synthesis of a protein β -turn mimetic" (1990) <i>J. Am. Chem. Soc.</i> 112 :323-333		
46.	Paglia, P. et al., "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo" (1996) <i>J. Exp. Med.</i> 183 :317-322		
47.	Pardoll, D.M., "Cancer vaccines" (1998) <i>Nature Med.</i> 4(5 Suppl.) :525-531		
48.	Parker, et al., "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2" (1992) <i>J. Immunol.</i> 149(11) :3580-3587		
49.	Parker, K.C. et al. (1995) "Peptide Binding to MHC Class I Molecules: Implications for Antigenic Peptide Prediction" <i>Immunol. Res.</i> 14 :34-57		
50.	Parkhurst, M.R. et al., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues" (1996) <i>J. Immunol.</i> 157 :2539-2548		
51.	al-Ramadi, B.K. et al., "Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR" (1992) <i>J. Immunol.</i> 155(2) :662-673		
52.	Rill, D.R. et al., "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" (1992) <i>Blood</i> 79(10) :2694-2700		
53.	Rouse, R.J.D. et al., "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins" (1994) <i>J. Virol.</i> 68(9) :5685-5689		
54.	Salazar, E. et al., "Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide" (2000) <i>Int. J. Cancer</i> 85 :829-838		
55.	Samanen, J. et al., "5,5-dimethylthiazolidine-4-carboxylic acid (DTC) as a proline analog with restricted		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

FEB 08 2002

PTO/SB/08 (2/92)
Sheet 4 of 4

TECH CENTER 1600/2900

RECEIVED

Form PTO-1449		Docket No. GZ 2104.00		TECH CENTER 1600/2900		App. No. 09/031,969	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				Applicant(s) Charles A. NICOLETTE			
				Filing Date: 08/17/2001		Group Art Unit: 1614	
		conformation" (1990) <i>Int. J. Peptide Protein Res.</i> 35 :501-509					
56.	X	Schlesinger, S. and T.W. Dubensky, Jr., "Alphavirus vectors for gene expression and vaccines" (1999) <i>Curr Opin Biotechnol.</i> 10 (5):434-439					
57.	X	Sette, A. et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes" (1994) <i>J. Immunol.</i> 153 (12):5586-5592					
58.	X	Shirai, M. et al., "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1" (1995) <i>J. Immunol.</i> 154 :2733-2742					
59.	X	Stuber, G. et al., "HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class 1 stabilization assay. Low proportion of binding motifs for several HLA class 1 alleles in EBNA-1" (1995) <i>Int. Immunol.</i> 7 (4):653-663					
60.	X	Tan, L. et al., "An improved assembly assay for peptide binding to HLA-B*2705 and H-2K*class I MHC molecules" (1997) <i>J. Immunol. Meth.</i> 209 (1):25-36					
61.	X	Tanguay, S. and J.J. Killion, "Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells" (1994) <i>Lymphokine Cytokine Res.</i> 13 (4):259-263					
62.	X	Valmori, D. et al., "Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue" (2000) <i>J. Immunol.</i> 164 (2):1125-1131					
63.	X	van der Burg, S.H. et al., "Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability" (1996) <i>J. Immunol.</i> 156 :3308-3314					
64.	X	Ware, C.F. et al., "Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line" (1983) <i>J. Immunol.</i> 131 (3):1312-1317					
65.	X	Wilchek, M. and E.A. Bayer, "The avidin-biotin complex in bioanalytical applications" (1988) <i>Anal. Biochem.</i> 171 :1-32					
66.	X	Ying, H. et al., "Cancer therapy using a self-replicating RNA vaccine" (1999) <i>Nat. Med.</i> 5 (7):823-827					
67.	X	Zabrocki, J. et al., "Conformational mimicry. 1. 1,5-disubstituted tetrazole ring as a surrogate for the cis amide bond" (1988) <i>J. Am. Chem. Sci.</i> 110 :5875-5880					
68.	X	Zechel, C. et al., "Synthetic glucagon antagonists and partial agonists" (1991) <i>Int. J. Pep. Protein Res.</i> 38 (2):131-138					
69.	X	Zuegel, et al., "Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues" (1998) <i>J. Immunol.</i> 161 (4):1705-1709					
70.	X	Zweerink, H.J. et al., "Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells" (1993) <i>J. Immunol.</i> 150 (5):1763-1771					
71.	X	Shin, Hiroshi et al., "Thrombin Receptor-Mediated Synovial Proliferation in Patients with Rheumatoid Arthritis" September (1995) <i>Clinical Immunology and Immunopathology</i> 76 (3):225-233					
72.	X	Henrikson, KP et al., "Role of Thrombin Receptor in Breast Cancer Invasiveness" (1999) <i>British J. of Cancer</i> 79 (3/4):401-406					
73.	X	Schmidt, Valentina A. et al., "The Human Proteinase-activated Receptor-3 (PAR-3) Gene" (1998) <i>The J. of Biological Chemistry</i> 273 (24) (Issue of June 12): 15061-15068					
74.	X	Zacharski, Leo R., M.D. et al., "Occurrence of Blood Coagulation Factors In Situ In Small Cell Carcinoma of the Lung" (1987) <i>Biology Library UCB Cancer</i> 60 :2675-2681					
75.	X	Zain, Jasmine et al., "Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells" (15 May 2000) <i>Blood</i> 85 (10):3133-3138					
76.	X	Ishihara, Hiroaki et al., "Antibodies to Protease-Activated Receptor 3 Inhibit Activation of Mouse Platelets by Thrombin" (1998) <i>Blood</i> 1 (11):4152-4157					
EXAMINER:				DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							



RECEIVED

PTO/USB/08 (2/92)

Sheet 5 of 5

Form PTO-1449	Docket No. GZ 2104.00	App. No. 09/931,969
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Charles A. NICOLETTE	TECH CENTER 1600/2900
(use several sheets if necessary)	Filing Date: 08/17/2001	Group Art Unit: 1614
77. <input checked="" type="checkbox"/>	Nierodzik, Mary Lynn et al., "Protease-Activated Receptor 1 (PAR-1) Required and Rate-Limiting for Thrombin-Enhanced Experimental Pulmonary Metastasis" (1998) <i>Blood</i> 92(10) :3694-3700	
78. <input checked="" type="checkbox"/>	Kaufmann, Roland et al., "PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells (1999) <i>J. of Neuro-Oncology</i> 42 :131-136	
79. <input checked="" type="checkbox"/>	Fischer, Edgar et al., "Tissue Factor-initiated Thrombin Generation Activates the Signaling Thrombin Receptor on Malignant Melanoma Cells" (1995) <i>Cancer Research</i> 55 :1629-1632	
80. <input checked="" type="checkbox"/>	Zacharski, L.R. "Small Cell Carcinoma of the Lung: Interaction with the Blood Coagulation Mechanism and Treatment with Anticoagulants" (4/1987) <i>National Library of Medicine Onkologie</i> 10 :264-270	
81. <input checked="" type="checkbox"/>	Schulman, Sam S., M.D. et al., "Incidence of Cancer After Prophylaxis With Warfarin Against Recurrent Venous Thromboembolism" (2000) <i>The New England J. of Medicine</i> 342(26) :1953-1958	
82. <input checked="" type="checkbox"/>	Zielinski, Christoph C., M.D. et al., "Warfarin for Cancer Prevention" (2000) <i>The New England Journal of Medicine</i> 342(26) :1-3	
83. <input checked="" type="checkbox"/>	Gorelik, Elieser, "Augmentation of the Antimetastatic Effect of Anticoagulant Drugs by Immunostimulation in Mice" (1987) <i>Cancer Research</i> 47 :809-815	
84. <input checked="" type="checkbox"/>	Neubauer, Blake Lee, "Inhibitory Effect of Warfarin on the Metastasis of the PAIII Prostatic Adenocarcinoma in the Rat" (1986) <i>The J. of Urology</i> 135 :163-166	
85. <input checked="" type="checkbox"/>	Ishihara H. et al., "Protease-activated receptor 3 is a second thrombin receptor in humans" (1997) <i>Nature</i> 386 :502-6	
86. <input checked="" type="checkbox"/>	Wojtukiewicz, Marek Z., et al., "Thrombin Increases the Metastatic Potential" (1993) <i>Int. J. Cancer</i> 54 :793-806	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	